Program
ixotatug vedotin
Also written as “TORL-1-23”, “TORL-1-23 and paclitaxel” and “TORL-1-23 and carboplatin”.
Its studies are mostly in Fallopian Tube Neoplasms · Ovarian Neoplasms · Carcinoma, Ovarian Epithelial, led by TORL Biotherapeutics.
Furthest: phase 2, since Nov 13, 20243 company-led studies, 3 open or runningNext primary completion: Oct 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TORL Biotherapeutics | 33 open or running | phase 2since Nov 13, 2024 | Oct 21, 2021 | Oct 2027phase 2 · NCT06690775 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 21, 2021First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT05103683 · 90 planned · United States, South Korea
- Nov 13, 2024Phase 2 study in Carcinoma, Ovarian EpithelialNCT06690775 · 230 planned · United States, Australia, Austria and more
- Dec 17, 2025Phase 2 study in Fallopian Tube NeoplasmsNCT07322094 · 60 planned · United States
Ahead
- Oct 2027Primary completion: phase 2 study in Carcinoma, Ovarian EpithelialNCT06690775
- Dec 2027Primary completion: phase 2 study in Fallopian Tube NeoplasmsNCT07322094
TargetBeta
CLDN6 →read by rule
“An antibody-drug conjugate (ADC) composed of ixotatug, a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 6 (CLDN6; CLDN-6), ”NCIt, by rule
Other programs on CLDN6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| CLDN6 RNA-LPX Vaccinerule | BioNTech | phase 2 | 1 |
| Anti-CLDN6/CD3 Bispecific Antibody XmAb541rule | Xencor | phase 1 | 2 |
| Anti-CLDN6/Anti-CD3 Bispecific Antibody BGB-B455rule | BeOne Medicines | phase 1 | 1 |
| Anti-Claudin 6 Antibody-drug Conjugate AT03-65rule | axcynsis-therapeutics-pte-ltd | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07322094Fallopian Tube Neoplasms · United States | 2 | Recruiting | Dec 2027 | 60 |
| NCT06690775Carcinoma, Ovarian Epithelial · United States, Australia, Austria and more | 2 | Recruiting | Oct 2027 | 230 |
| NCT05103683Ovarian Neoplasms · United States, South Korea | 1 | Recruiting | Aug 31, 2026 | 90 |
How it is read
Names in the registry
- “TORL-1-23”, 4 entries
- “TORL-1-23 and paclitaxel”, 1 entry
- “TORL-1-23 and carboplatin”, 1 entry
- “TORL-1-23, paclitaxel, and carboplatin”, 1 entry
Conditions, from the studies’ own filings
- Fallopian Tube Neoplasms, 1 study
- Ovarian Neoplasms, 1 study
- Carcinoma, Ovarian Epithelial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.